Diabetes and cardiovascular disease: Is intensive glucose control beneficial or deadly? lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR

Wiener Medizinische Wochenschrift

Volumn 160, Issue 1-2, 2010, Pages 8-19

  Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

ACCORD; ADVANCE; Cardiovascular disease; Diabetes; DIGAMI; Glycemic control; NICE SUGAR; PROactive; RECORD; VADT

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; REPAGLINIDE; SULFONYLUREA;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE DURATION; DISEASE SEVERITY; HEART ARREST; HEART DEATH; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; WEIGHT GAIN;

AGE FACTORS; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SURVIVAL RATE; WEIGHT GAIN;

EID: 77949833491     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0748-7     Document Type: Review

References (66)

1. KH Yoon JH Lee JW Kim, et al. 2006 Epidemic obesity and type 2 diabetes in Asia Lancet 368 1681 1688 10.1016/S0140-6736(06)69703-1 17098087 (Pubitemid 46048556)
2. G Schernthaner 1996 Cardiovascular mortality and morbidity in type-2 diabetes mellitus Diabetes Res Clin Pract 31 Suppl S3 S13 10.1016/0168-8227(96) 01224-7 8864635 (Pubitemid 26258874)
3. SR Preis SJ Hwang S Coady, et al. 2009 Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 Circulation 119 1728 1735 10.1161/CIRCULATIONAHA.108.829176 19307472
4. R Turner H Millns H Neil, et al. 1998 Risk factors for coronary artery disease in non-insulin dependant diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) BMJ 316 823 828 1:STN:280:DyaK1c3htVKhsg%3D%3D 9549452
5. The DECODE Study Grou on behalf of the European Diabetes Epidemiology Group 2003 Is the current definition of diabetes relevant to mortality risk from all causes and cardiovascular and non-cardiovascular diseases? Diabetes Care 26 688 696 10.2337/diacare.26.3.688 (Pubitemid 36929329)
6. Asia Pacific Cohort Studies Collaboration 2004 BG and risk of cardiovascular disease in the Asia Pacific region Diabetes Care 27 2836 2842 10.2337/diacare.27.12.2836 (Pubitemid 39565046)
7. KT Khaw N Wareham R Luben, et al. 2001 Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 15 18 10.1136/bmj.322.7277.15 1:STN:280:DC%2BD3M7mt1ejuw%3D%3D 11141143
8. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
9. A Juutilainen S Lehto T Rönnemaa, et al. 2008 Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects Diabetes Care 31 714 719 10.2337/dc07-2124 18083789
10. HC Gerstein ME Miller RP Byington, et al. 2008 Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545 2559 10.1056/NEJMoa0802743 1:CAS:528:DC%2BD1cXnt1Wjs7s%3D 18539917
11. A Patel S MacMahon J Chalmers, et al. 2008 ; ADVANCE Collaborative Group Intensive BG control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 2560 2572 1:CAS:528:DC%2BD1cXnt1yht7s%3D
12. W Duckworth C Abraira T Moritz, et al. 2009 Intensive glucose control and complications in American veterans with type 2 diabetes N Engl J Med 360 129 139 10.1056/NEJMoa0808431 1:CAS:528:DC%2BD1MXnsFWkug%3D%3D 19092145
13. C Abraira WC Duckworth T Moritz VADT Group 2009 Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report Diabetes Obes Metab 11 150 156 10.1111/j.1463-1326.2008.00933.x 1:CAS:528:DC%2BD1MXivVWjtLo%3D 18671796
14. SR Preis MJ Pencina SJ Hwang, et al. 2009 Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study Circulation 120 212 220 10.1161/CIRCULATIONAHA.108.846519 19581493
15. S Greenfield J Billimek F Pellegrini, et al. 2009 Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study Ann Intern Med 151 854 860 20008761
16. G Schernthaner A Grimaldi U Di Mario, et al. 2004 GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients Eur J Clin Invest 34 535 542 10.1111/j.1365-2362.2004.01381.x 1:CAS:528:DC%2BD2cXnslOhtrk%3D 15305887 (Pubitemid 39120222)
17. P Choudhary K Lonnen CJ Emery, et al. 2009 Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes Diabet Med 26 665 672 10.1111/j.1464-5491. 2009.02759.x 1:CAS:528:DC%2BD1MXpvFeksr8%3D 19573114
18. L Landstedt-Hallin A Englund U Adamson, et al. 1999 Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus J Intern Med 246 299 307 10.1046/j.1365-2796.1999.00528.x 1:STN:280: DyaK1Mvgs1Oltg%3D%3D 10475998 (Pubitemid 29426449)
19. C Desouza H Salazar B Cheong, et al. 2003 Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring Diabetes Care 26 1485 1489 10.2337/diacare.26.5.1485 12716809 (Pubitemid 36929183)
20. NP Murphy ME Ford-Adams KK Ong, et al. 2004 Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes Diabetologia 47 1940 1947 10.1007/s00125-004- 1552-y 1:STN:280:DC%2BD2cnitlGisA%3D%3D 15551045 (Pubitemid 40110202)
21. DN Laptev GV Riabykina AA Seid-Guseinov 2009 24-hours monitoring of ECG and glucose level for detection of relations between glycemia and QT interval duration in patients with type 1 diabetes Ter Arkh 81 28 33 1:STN:280: DC%2BD1MvgvFWjsA%3D%3D 19514418
22. DJ Ewing O Boland JM Neilson, et al. 1991 Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients Diabetologia 34 182 185 10.1007/BF00418273 1:STN:280:DyaK3MzlslalsA%3D%3D 1884890
23. RT Robinson ND Harris RH Ireland, et al. 2003 Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia Diabetes 52 1469 1474 10.2337/diabetes.52.6.1469 1:CAS:528:DC%2BD3sXmt1SjsrY%3D 12765959 (Pubitemid 36666203)
24. GV Gill A Woodward IF Casson, et al. 2009 Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes - the 'dead in bed' syndrome revisited Diabetologia 52 42 45 10.1007/s00125-008-1177-7 1:STN:280: DC%2BD1cjotVKnsg%3D%3D 18972096
25. Diabetes Control and Complications Trial Research Group 1995 Effect of intensive diabetes management on macrovascular disease and risk factors in the Diabetes Control and Complications Trial Am J Cardiol 75 894 903 10.1016/S0002-9149(99)80683-3
26. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
27. DM Nathan PA Cleary JY Backlund, et al. 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2643 2653 10.1056/NEJMoa052187 16371630 (Pubitemid 41817713)
28. RR Holman SK Paul MA Bethel, et al. 2008 10-year follow-up of intensive glucoseh control in type 2 diabetes N Engl J Med 359 1577 1589 10.1056/NEJMoa0806470 1:CAS:528:DC%2BD1cXht1Wgt7nK 18784090
29. UK Prospective 9. Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854 865 10.1016/S0140-6736(98)07037-8 (Pubitemid 28416719)
30. G Zhou R Myers Y Li, et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 1167 1174 1:CAS:528: DC%2BD3MXns1ChsL4%3D 11602624
31. R Prager G Schernthaner 1983 Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics Diabetes 32 1083 1086 10.2337/diabetes.32.12.1083 1:STN:280:DyaL2c%2FosFGhtg%3D%3D 6360756
32. R Prager G Schernthaner H Graf 1986 Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus Diabete Metab 12 346 350 1:STN:280:DyaL2s7jsVCrug%3D%3D 3817257
33. JA Dormandy B Charbonnel DJ Eckland, et al. 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279 1289 10.1016/S0140-6736(05)67528-9 1:CAS:528:DC%2BD2MXhtVOlu7fO 16214598 (Pubitemid 41416583)
34. E Erdmann JA Dormandy B Charbonnel, et al. 2007 The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) study J Am Coll Cardiol 49 1772 1780 10.1016/j.jacc.2006.12.048 1:CAS:528:DC%2BD2sXkslCgsLs%3D 17466227 (Pubitemid 46629127)
35. R Wilcox M-G Bousser J Betteridge, et al. 2007 Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke Stroke 38 865 873 10.1161/01.STR.0000257974.06317.49 1:CAS:528:DC%2BD2sXhslygur8%3D 17290029 (Pubitemid 46568445)
36. E Mannucci M Monami C Lamanna, et al. 2008 Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials Diabetes Obes Metab 10 1221 1238 10.1111/j.1463-1326.2007.00724.x 1:CAS:528:DC%2BD1MXlvVaqsw%3D%3D 18505403
37. AM Lincoff K Wolski SJ Nicholls, et al. 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 10.1001/jama.298.10.1180 1:CAS:528:DC%2BD2sXhtVGmtL3J 17848652 (Pubitemid 47403104)
38. G Schernthaner 2009 Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors Int J Clin Pract 63 912 929 10.1111/j.1742-1241.2009.02025.x 1:STN:280:DC%2BD1MzovFOntw%3D%3D 19490202
39. BARI 2D Study Group 2009 A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med 360 2503 2515 10.1056/NEJMoa0805796
40. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 2010 (in press)
41. G Schernthaner DR Matthews B Charbonnel, et al. 2004 Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial J Clin Endocrinol Metab 89 6068 6076 10.1210/jc.2003-030861 1:CAS:528:DC%2BD2cXhtFSit77J 15579760 (Pubitemid 39628416)
42. BH Charbonnel DR Matthews G Schernthaner, et al. 2005 A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial Diabet Med 22 399 405 10.1111/j.1464-5491.2004.01426.x 1:CAS:528:DC%2BD2MXktVOntb4%3D 15787663 (Pubitemid 40516237)
43. JM Gamble SH Simpson DT Eurich, et al. 2010 Insulin use and increased risk of mortality in type 2 diabetes: a cohort study Diabetes Obes Metab 12 47 53 10.1111/j.1463-1326.2009.01125.x 1:CAS:528:DC%2BC3cXhvFajtLY%3D 19788429
44. K Malmberg A Norhammar H Wedel, et al. 1999 Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study Circulation 99 2626 2632 1:CAS:528:DyaK1MXjvVKmtrw%3D 10338454
45. K Malmberg L Rydén H Wedel, et al. 2005 Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2) effects on mortality and morbidity Eur Heart J 26 650 651 10.1093/eurheartj/ehi199 1:CAS:528:DC%2BD2MXksFGnsrk%3D 15728645 (Pubitemid 40516876)
46. LG Mellbin K Malmberg A Norhammer, et al. 2008 The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial Eur Heart J 29 166 176 10.1093/eurheartj/ehm518 1:CAS:528:DC%2BD1cXivVOqu7o%3D 18156614
47. I Raz PW Wilson K Strojek, et al. 2009 Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial Diabetes Care 32 381 386 10.2337/dc08-1671 1:CAS:528:DC%2BD1MXjvVyqsbk%3D 19246588
48. M Anselmino J Ohrvik K Malmberg, et al. 2008 Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the EuroHeart Survey on Diabetes and the Heart Eur Heart J 29 177 184 10.1093/eurheartj/ehm519 18156611
49. LG Mellbin K Malmberg A Waldenstrom, et al. 2009 Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial Heart 95 721 727 10.1136/hrt.2008.152835 1:STN:280:DC%2BD1M3ns1aisA%3D%3D 19029171
50. M Kosiborod SE Inzucchi A Goyal, et al. 2009 Relationship between spontaneous and iatrogenic hypoglycaemia and mortality in patients hospitalized with acute myocardial infarction JAMA 301 1556 1564 10.1001/jama.2009.496 1:CAS:528:DC%2BD1MXksVyks7o%3D 19366775
51. A Goyal SR Mehta R Díaz, et al. 2009 Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction Circulation 120 2429 2437 10.1161/CIRCULATIONAHA.108.837765 1:CAS:528:DC%2BD1MXhsFSqtb3O 19948980
52. M Kosiborod SS Rathore SE Inzucchi, et al. 2005 Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes Circulation 111 3078 3086 10.1161/CIRCULATIONAHA.104.517839 1:CAS:528:DC%2BD2MXkvVCmurY%3D 15939812 (Pubitemid 40847785)
53. G Van den Berghe P Wouters F Weekers, et al. 2001 Intensive insulin therapy in critically ill patients N Engl J Med 345 1359 1367 10.1056/NEJMoa011300 1:CAS:528:DC%2BD3MXot1aquro%3D 11794168
54. G Van den Berghe A Wilmer G Hermans, et al. 2006 Intensive insulin therapy in the medical ICU N Engl J Med 354 449 461 10.1056/NEJMoa052521 1:CAS:528:DC%2BD28XptFGksA%3D%3D 16452557 (Pubitemid 43200296)
55. G Van den Berghe A Wilmer, et al. 2006 Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm Diabetes 55 3151 3159 10.2337/db06-0855 1:CAS:528:DC%2BD28XhtF2rtr%2FJ 17065355
56. The NICE-SUGAR study investigators 2009 Intensive versus conventional glucose control in critically ill patients N Engl J Med 360 1283 1297 10.1056/NEJMoa0810625
57. KK Ray SR Seshasai S Wijesuriya, et al. 2009 Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 1765 1772 10.1016/S0140-6736(09)60697-8 1:CAS:528:DC%2BD1MXmtleksbc%3D 19465231
58. FM Turnbull C Abraira RJ Anderson, et al. 2009 Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288 2298 10.1007/s00125-009-1470-0 1:CAS:528:DC%2BD1MXht1Cis7jI 19655124
59. TN Kelly LA Bazzano VA Fonseca, et al. 2009 Systematic review: glucose control and cardiovascular disease in type 2 diabetes Ann Intern Med 151 394 403 19620144
60. E Mannucci M Monami C Lamanna, et al. 2009 Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 19 604 612 10.1016/j.numecd.2009.03.021 1:STN:280:DC%2BD1MjhsVyrtw%3D%3D 19427768
61. PM Kearney L Blackwell Cholesterol Treatment Trialists' (CTT) Collaborators 2008 Lancet 371 117 10.1016/S0140-6736(08)60761-8 1:STN:280:DC%2BD1c%2FjvVWmsg%3D%3D 18191683
62. R Collins, et al. 2008 Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 17 25 10.1016/S0140-6736(08)60052-5
63. F Turnbull B Neal C Algert, et al. 2005 Blood pressure lowering treatment trialists' Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 1410 1419
64. P Gaede H Lund-Andersen HH Parving, et al. 2008 Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580 591 10.1056/NEJMoa0706245 1:CAS:528:DC%2BD1cXhs1entLc%3D 18256393
65. P Gaede P Vedel N Larsen, et al. 2003 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383 393 10.1056/NEJMoa021778 12556541 (Pubitemid 36159355)
66. JS Skyler R Bergenstal RO Bonow, et al. 2009 Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American diabetes Association and a scientific statement of the American college of cardiology foundation and the American heart association Circulation 119 351 357 10.1161/CIRCULATIONAHA.108.191305 19095622